Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Aug 13;100(32):e26849.
doi: 10.1097/MD.0000000000026849.

Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis

Luting Liu  1 , Wanchun Xiong
Affiliations
Meta-Analysis

Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis

Luting Liu et al. Medicine (Baltimore). .

Abstract

This study aimed to investigate the effect of molecular targeted agents (MTAs) in chemo on platinum-resistant recurrent ovarian cancer (ROC). We performed this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements. Randomized controlled trials reporting data about platinum-resistant ovarian cancer treated by MTAs were included. The endpoints for the present study included overall survival and progression-free survival. We analyzed 9 randomized controlled trials including 3631 patients with ROC. The pooled analysis indicated that a combination of MTAs with chemo could markedly increase objective response rate in those patients (P = .012). Nevertheless, the survival rate of those patients was not markedly changed (P = .19). Besides, the combination of MTAs with chemo dramatically aggravated the occurrence of adverse events (P < .05). Moreover, it resulted in the termination of treatment (P = .044) in those patients, but it had no effect on fatal adverse events (P = .16). Our results indicated that the combination of MTAs with chemo notably improved objective response rate in patients with platinum-resistant ROC, but its benefit did not translate into survival benefits.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Figure 2
Random-effect model of hazard ratio (95%CI) of PFS associated with chemotherapy with or without TAs in ROC patients. CI = confidence interval, PFS = progression-free survival, ROC = recurrent ovarian cancer, TAs = targeted agents.
Figure 3
Figure 3
Fixed-effects model of relative ratio (95%CI) of ORR associated with chemotherapy with or without TAs in ROC patients. CI = confidence interval, ORR = objective response rate, ROC = recurrent ovarian cancer, TAs = targeted agents.
Figure 4
Figure 4
Fixed-effects model of relative ratio (95%CI) of AEs leads to treatment discontinuation associated with chemotherapy with or without TAs in ROC patients. AEs = adverse events, CI = confidence interval, ROC = recurrent ovarian cancer, TAs = targeted agents.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Baldwin LA, Huang B, Miller RW, et al. . Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012;120:612–8. - PubMed
    1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019. - PubMed
    1. Vergote I, Debruyne P, Kridelka F, et al. . Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol 2015;138:278–84. - PubMed
    1. Lee MX, Tan DS. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? J Gynecol Oncol 2018;29:e96. - PMC - PubMed

MeSH terms

Substances